Nav: Home

Umbralisib shows early promise for patients with marginal zone lymphoma

April 01, 2019

ATLANTA -- The investigational therapeutic umbralisib, which targets the molecule PI3K-delta, was well tolerated and highly active in patients with relapsed/refractory marginal zone lymphoma, according to early results from the UNITY-NHL phase II clinical trial, which were presented at the AACR Annual Meeting 2019, March 29-April 3.

As of October 20, 2018, 55 percent of patients who had at least six months of follow-up had a partial or complete response following umbralisib treatment. The median duration of response had not been reached. Updated data will be presented at the meeting, according to Nathan H. Fowler, MD, associate professor of medicine and director of clinical research in the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer Center in Houston.

In January 2019, the U.S. Food and Drug Administration (FDA) granted umbralisib breakthrough therapy designation for the treatment of adults with marginal zone lymphoma who have received at least one anti-CD20 treatment. Breakthrough therapy designation is an FDA strategy to expedite assessment of therapeutics for life-threatening diseases such as cancer.

"Marginal zone lymphoma is an uncommon, slow-growing type of non-Hodgkin lymphoma," said Fowler. "Rituximab, either alone or in combination with chemotherapy, has improved outcomes for patients, but in most cases the disease eventually relapses, and these individuals have limited treatment options.

"Umbralisib is a small-molecule inhibitor that targets PI3K-delta, which is a component of a signaling pathway that has a key role in promoting the survival and expansion of many types of cells, and has also been shown to uniquely inhibit CK1 epsilon," continued Fowler. "Our exciting results suggest that this oral targeted therapeutic has significant activity against relapsed/refractory marginal zone lymphoma and offers hope for patients."

As of October 20, 2018, 69 patients with relapsed/refractory marginal zone lymphoma had been enrolled on the trial and received 800 milligrams of umbralisib orally once daily until disease progression or unacceptable toxicity. At that time, 38 patients had at least six months of follow-up.

Among the 38 patients, the median follow-up time was 9.6 months. Four had a complete response and 17 had a partial response, as assessed by the investigators, for an overall response rate of 55 percent. An additional 11 patients had stable disease, for a clinical benefit rate (complete response, partial response, and stable disease) of 84 percent. Progression-free survival at 12 months was 71 percent.

The most common adverse event of any grade was diarrhea, which affected 45 percent of the 38 patients. Nausea, fatigue, headache, cough, and decreased appetite affected between 20 percent and 30 percent of patients. The most common grade 3/4 adverse events were neutropenia, febrile neutropenia, and diarrhea, which affected 8 percent, 5 percent, and 5 percent of the 38 patients, respectively. No events of colitis or pneumonitis had been reported.

"All the adverse events we have seen in the trial are to be expected with this class of drugs," said Fowler. "Moreover, we were able to manage the side effects for the patients, making umbralisib a well-tolerated treatment.

"The adverse event and clinical activity data are highly encouraging at this early timepoint," added Fowler. "We are excited to continue following patients for a longer time to further establish the long-term activity and side effects of umbralisib. With the results reported so far, umbralisib has the potential to make a real difference for patients with relapsed/refractory marginal zone lymphoma."

According to Fowler, the main limitations of the data presented are that it was based on a small number of patients and a short follow-up time.
This study was funded by TG Therapeutics. Fowler serves on scientific advisory boards for TG Therapeutics, Bayer, Gilead Sciences, and Verastem Oncology; he also receives research funding from TG Therapeutics.

American Association for Cancer Research

Related Side Effects Articles:

Popular prostate drug linked to serious side effects
Treatment of benign prostatic hyperplasia (BPH) with the commonly prescribed Avodart (Dutsteride) may put men at an increased risk for diabetes, elevated cholesterol levels, non-alcoholic fatty liver disease (NAFLD) and worsening erectile dysfunction.
Previously unpublished trial data explain effects and side effects of key MS drug
Through a Freedom of Information request to the European Medicines Agency, researchers from Queen Mary University of London (QMUL) gained access to the phase III trial datasets of Alemtuzumab, and publish new insights (JAMA Neurology) into the drastic response of the immune system in patients with MS.
Painkillers without dangerous side effects
Researchers from Charité - Universitätsmedizin Berlin have discovered a new way of developing painkillers.
Measuring patients' muscles to predict chemotherapy side effects
Researchers at the University of North Carolina Lineberger Comprehensive Cancer Center report in the journal Clinical Cancer Research that measuring patients' muscle mass and quality could potentially help doctors better identify patients at high risk for toxic side effects that could require hospitalizations.
Ground-breaking research on the side effects of therapy
While many people who suffer from depression and anxiety are helped by seeing a psychologist, others don't get better or actually get worse.
Naturally occurring symptoms may be mistaken for tamoxifen side-effects
Women taking tamoxifen to prevent breast cancer were less likely to continue taking the drug if they suffered nausea and vomiting, according to new data presented at the San Antonio Breast Cancer Symposium.
An appetite suppressant with side effects
Neurogeneticists from the University of Würzburg have discovered a peptide in Drosophila that has a strong impact on the fly's feeding and sleeping habits.
Dopamine receptor blockade seen as cause for antipsychotic drug side-effects
University of California, Irvine scientists led by Emiliana Borrelli and colleagues have discovered the key cellular mechanism that underlies the antipsychotic-induced parkinsonism -- which includes involuntary movements, tremors and other severe physical conditions.
Predicting potential pharma side effects
A computer program that can predict whether or not a given pharmaceutical will have worrying side effects has been developed by researchers in the USA.
Reduced side effects from ECT for those with severe depression
Despite its effectiveness, use of ECT remains limited due to concerns about side effects.

Related Side Effects Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Moving Forward
When the life you've built slips out of your grasp, you're often told it's best to move on. But is that true? Instead of forgetting the past, TED speakers describe how we can move forward with it. Guests include writers Nora McInerny and Suleika Jaouad, and human rights advocate Lindy Lou Isonhood.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...